CA
LXRX icon

Cetera Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Cetera Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$25.6K Buy
+10,675
New +$22.9K ﹤0.01% 2389

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Cetera Advisors's LXRX Position: Q1 2024 in Review

Cetera Advisors opened a new position in Lexicon Pharmaceuticals (LXRX) in Q1 2024: 10,675 shares worth $25.6K. The stake represents ﹤0.01% of the portfolio and ranks #2389 among its holdings.

119 funds tracked by Wall St. Rank hold LXRX as of Q1 2024.

  • Cetera Advisors held 10,675 shares of Lexicon Pharmaceuticals worth $25.6K as of Q1 2024.
  • Lexicon Pharmaceuticals was a new Cetera Advisors position in Q1 2024.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Cetera Advisors's portfolio in Q1 2024, its #2389 holding.
  • 119 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.